Name (Synonyms) | Correlation | |
---|---|---|
drug1236 | Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This trial is designed to evaluate the efficacy and safety of moxibustion plus cupping in the convalescence of COVID-19.
Description: At the end of week 4, the average visual analogue scale (VAS) score of main clinical symptoms in the past 1 week changed from baseline. The VAS score ranges from 0 to 100 point and the higher scores mean worse symptoms (The main clinical symptoms including: Cough /chest tightness/shortness of breath after exercise/asthenia).
Measure: The change of the average VAS score from baseline to week 4 Time: week 4Description: At the end of week 2, week 4 and week 8, the average VAS score of main clinical symptoms in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 2, and week 8 Time: week 2 and week 8Description: At the end of week 2, week 4 and week 8, the severity VAS score of main clinical symptoms in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the severity VAS score from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the average insomnia VAS score in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the average insomnia VAS score from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the average VAS score of sweating, mental fatigue, anorexia and nervousness in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score of sweating, mental fatigue, anorexia and nervousness from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the average times of diarrhea and complete spontaneous bowel movement in the past 1 week changed from baseline.
Measure: The change of the average times of diarrhea and complete spontaneous bowel movement to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the proportion of patients whose average and severity VAS scores of main clinical symptoms (except diarrhea and constipation) in the past 1 week changed from baseline decreased 50% and 75%. VAS score measure is as same as the primary outcome.
Measure: The proportion of patients with 50%/75% improvement of clinical symptoms to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the walking distance of six-minute-walking test changed from baseline.
Measure: The change of the walking distance of six-minute-walking test from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the lowest oxygen saturation of six-minute-walking test changed from baseline.
Measure: The change of the lowest oxygen saturation of six-minute-walking test from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2 and week 4, the proportion of patients in recovery of pulmonary function in all participants.
Measure: The proportion of patients in recovery of pulmonary function on week 2 and week 4 Time: week 2 and week 4Description: Lung CT shows complete absorption of inflammation.
Measure: The proportion of patients whose lung CT return to normal on week 4 Time: week 4Description: At the end of week 4 and week 8, the WHO Quality of Life-BREF (WHO QOL-BREF) score changed from baseline. The higher scores mean better outcome.
Measure: The change of the WHO QOL-BREF score from baseline to week 4 and week 8 Time: week 4 and week 8Description: At the end of week 4 and week 8, the Self-Rating Anxiety Scale (SAS) score changed from baseline. The higher scores mean worse outcome.
Measure: The change of the SAS score from baseline to week 4 and week 8 Time: week 4 and week 8Description: At the end of week 4 and week 8, the Self-Rating Depression Scale (SDS) score changed from baseline.The higher scores mean worse outcome.
Measure: The change of the SDS score from baseline to week 4 and week 8 Time: week 4 and week 8Description: At the end of week 4, the blood C-reactive protein (CRP) value changed from baseline.
Measure: The change of the blood CRP value from baseline to week 4 Time: week 4Description: At the end of week 4, the blood lymphocyte count (LYMPH#) changed from baseline.
Measure: The change of the blood LYMPH# value from baseline to week 4 Time: week 4Description: At the end of week 4, the percentage of blood neutrophils (NEUT%) value changed from baseline.
Measure: The change of the blood NEUT% value from baseline to week 4 Time: week 4Description: Divide the patients into two subgroups (the non-elderly ≤ 40 years old; the elderly > 40 years old ) according to the baseline data. At the end of week 4, analyze the average VAS score of main clinical symptoms in the past 1 week changed from baseline in the two age groups. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 4 in different age groups. Time: week 4Description: Divide the patients into two subgroups (man; woman) according to the baseline data. At the end of week 4, analyze the average VAS score of main clinical symptoms in the past 1 week changed from baseline in the two gender groups. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 4 in different gender groups. Time: week 4Description: Divide the patients into four subgroups ( mild type;common type;severe type;critical type) according to the baseline data. At the end of week 4, analyze the average VAS score of main clinical symptoms in the past 1 week changed from baseline in the four clinical classification groups. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 4 in different clinical classification of COVID-19. Time: week 4